BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Current progress on development of respiratory syncytial virus vaccine

  • Chang, Jun (College of Pharmacy, and Division of Life & Pharmaceutical Sciences, Ewha Womans University)
  • Accepted : 2011.03.23
  • Published : 2011.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to certain vaccine candidates leading to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. A wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vector-based candidates. Though licensed vaccines remain to be developed, our great efforts will lead us to reach the goal of attaining safe and effective RSV vaccines in the near future.

Keywords

References

  1. Hall, C. B., Walsh, E. E., Long, C. E. and Schnabel, K. C.(1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect Dis. 163, 693-698. https://doi.org/10.1093/infdis/163.4.693
  2. Walsh, E. E., Hall, C. B., Briselli, M., Brandriss, M. W. andSchlesinger, J. J. (1987) Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J. Infect Dis. 155, 1198-1204. https://doi.org/10.1093/infdis/155.6.1198
  3. Connors, M., Collins, P. L., Firestone, C. Y. and Murphy,B. R. (1991) Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65, 1634-1637.
  4. Johnson, P. R., Spriggs, M. K., Olmsted, R. A. and Collins,P. L. (1987) The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. U.S.A. 84, 5625-5629. https://doi.org/10.1073/pnas.84.16.5625
  5. Johnson, S., Oliver, C., Prince, G. A., Hemming, V. G.,Pfarr, D. S., Wang, S. C., Dormitzer, M., O'Grady, J.,Koenig, S., Tamura, J. K., Woods, R., Bansal, G., Couchenour,D., Tsao, E., Hall, W. C. and Young, J. F. (1997) Development of a humanized monoclonal antibody (MEDI- 493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect Dis. 176, 1215-1224. https://doi.org/10.1086/514115
  6. Graham, B. S., Bunton, L. A., Wright, P. F. and Karzon, D.T. (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88, 1026-1033. https://doi.org/10.1172/JCI115362
  7. Alwan, W. H., Record, F. M. and Openshaw, P. J. (1992)CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin. Exp. Immunol. 88, 527-536.
  8. Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff,R. A. and Stewart, C. E. (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421. https://doi.org/10.1093/oxfordjournals.aje.a120954
  9. Murphy, B. R. and Walsh, E. E. (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion- inhibiting activity. J. Clin. Microbiol. 26, 1595-1597.
  10. Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. andAnderson, L. J. (1996) Respiratory synctial virus infection in BALB/c mice previously immunized with formalininactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70, 2852-2860.
  11. De Swart, R. L., Kuiken, T., Timmerman, H. H., vanAmerongen, G., Van Den Hoogen, B. G., Vos, H. W.,Neijens, H. J., Andeweg, A. C. and Osterhaus, A. D. (2002) Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76, 11561-11569. https://doi.org/10.1128/JVI.76.22.11561-11569.2002
  12. Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C.Y., Morse, H. C. 3rd and Murphy, B. R. (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin- 4 (IL-4) and IL-10. J. Virol. 68, 5321-5325.
  13. Levine, S., Klaiber-Franco, R., and Paradiso, P. R. (1987) Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 68(Pt 9), 2521-2524. https://doi.org/10.1099/0022-1317-68-9-2521
  14. Taylor, G., Stott, E. J., Bew, M., Fernie, B. F., Cote, P. J.,Collins, A. P., Hughes, M. and Jebbett, J. (1984) Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52, 137-142.
  15. Sparer, T. E., Matthews, S., Hussell, T., Rae, A. J., Garcia-Barreno, B., Melero, J. A. and Openshaw, P. J. (1998)Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187, 1921-1926. https://doi.org/10.1084/jem.187.11.1921
  16. Martinez, I. and Melero, J. A. (1998) Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J. Gen. Virol. 79(Pt 9), 2215-2220. https://doi.org/10.1099/0022-1317-79-9-2215
  17. Bastien, N., Trudel, M. and Simard, C. (1999) Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 17, 832-836. https://doi.org/10.1016/S0264-410X(98)00267-9
  18. Srikiatkhachorn, A. and Braciale, T. J. (1997) Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186, 421-432. https://doi.org/10.1084/jem.186.3.421
  19. Martinez, I., Dopazo, J. and Melero, J. A. (1997) Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J. Gen. Virol. 78(Pt 10), 2419-2429. https://doi.org/10.1099/0022-1317-78-10-2419
  20. Connors, M., Kulkarni, A. B., Collins, P. L., Firestone, C.Y., Holmes, K. L., Morse, H. C. 3rd and Murphy, B. R.(1992) Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 66, 1277-1281.
  21. Nicholas, J. A., Rubino, K. L., Levely, M. E., Adams, E. G.and Collins, P. L. (1990) Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J. Virol. 64, 4232-4241.
  22. Heidema, J., de Bree, G. J., De Graaff, P. M., van Maren,W. W., Hoogerhout, P., Out, T. A., Kimpen, J. L. and van Bleek, G. M. (2004) Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J. Gen. Virol. 85, 2365-2374. https://doi.org/10.1099/vir.0.80131-0
  23. Johnson, T. R., Johnson, J. E., Roberts, S. R., Wertz, G. W.,Parker, R. A. and Graham, B. S. (1998) Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72, 2871-2880.
  24. Openshaw, P. J., Clarke, S. L. and Record, F. M. (1992)Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4, 493-500. https://doi.org/10.1093/intimm/4.4.493
  25. Hancock, G. E., Speelman, D. J., Heers, K., Bortell, E.,Smith, J. and Cosco, C. (1996) Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70, 7783-7791.
  26. Tebbey, P. W., Hagen, M. and Hancock, G. E. (1998)Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188, 1967-1972. https://doi.org/10.1084/jem.188.10.1967
  27. Johnson, T. R., Varga, S. M., Braciale, T. J. and Graham,B. S. (2004) Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin- inactivated RSV. J. Virol. 78, 8753-8760. https://doi.org/10.1128/JVI.78.16.8753-8760.2004
  28. Johnson, T. R., Teng, M. N., Collins, P. L. and Graham, B.S. (2004) Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78, 6024-6032. https://doi.org/10.1128/JVI.78.11.6024-6032.2004
  29. Crowe, J. E. Jr., Firestone, C. Y. and Murphy, B. R. (2001)Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J. Immunol. 167, 3910-3918. https://doi.org/10.4049/jimmunol.167.7.3910
  30. Glezen, W. P., Taber, L. H., Frank, A. L. and Kasel, J. A.(1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543-546.
  31. Henderson, F. W., Collier, A. M., Clyde, W. A. Jr. andDenny, F. W. (1979) Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300, 530-534. https://doi.org/10.1056/NEJM197903083001004
  32. Bukreyev, A., Yang, L., Fricke, J., Cheng, L., Ward, J. M.,Murphy, B. R. and Collins, P. L. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor- bearing leukocytes. J. Virol. 82, 12191-12204. https://doi.org/10.1128/JVI.01604-08
  33. Chang, J. and Braciale, T. J. (2002) Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat. Med. 8, 54-60. https://doi.org/10.1038/nm0102-54
  34. Schlender, J., Walliser, G., Fricke, J. and Conzelmann, K.K. (2002) Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact. J. Virol. 76, 1163-1170. https://doi.org/10.1128/JVI.76.3.1163-1170.2002
  35. Pringle, C. R., Filipiuk, A. H., Robinson, B. S., Watt, P. J.,Higgins, P. and Tyrrell, D. A. (1993) Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11, 473-478. https://doi.org/10.1016/0264-410X(93)90290-E
  36. Wright, P. F., Karron, R. A., Belshe, R. B., Thompson, J.,Crowe, J. E. Jr., Boyce, T. G., Halburnt, L. L., Reed, G. W.,Whitehead, S. S., Anderson, E. L., Wittek, A. E., Casey, R.,Eichelberger, M., Thumar, B., Randolph, V. B., Udem, S.A., Chanock, R. M. and Murphy, B. R. (2000) Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182, 1331-1342. https://doi.org/10.1086/315859
  37. Karron, R. A., Wright, P. F., Belshe, R. B., Thumar, B.,Casey, R., Newman, F., Polack, F. P., Randolph, V. B.,Deatly, A., Hackell, J., Gruber, W., Murphy, B. R. andCollins, P. L. (2005) Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191, 1093-1104. https://doi.org/10.1086/427813
  38. Wright, P. F., Karron, R. A., Madhi, S. A., Treanor, J. J.,King, J. C., O'Shea, A., Ikizler, M. R., Zhu, Y., Collins, P.L., Cutland, C., Randolph, V. B., Deatly, A. M., Hackell, J.G., Gruber, W. C. and Murphy, B. R. (2006) The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect Dis. 193, 573-581. https://doi.org/10.1086/499600
  39. Murphy, B. R., Sotnikov, A. V., Lawrence, L. A., Banks, S.M. and Prince, G. A. (1990) Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8, 497-502. https://doi.org/10.1016/0264-410X(90)90253-I
  40. Murphy, B. R., Sotnikov, A., Paradiso, P. R., Hildreth, S.W., Jenson, A. B., Baggs, R. B., Lawrence, L., Zubak, J. J.,Chanock, R. M., Beeler, J. A. and Prince, G. A. (1989)Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7, 533-540. https://doi.org/10.1016/0264-410X(89)90278-8
  41. Prince, G. A., Denamur, F., Deschamps, M., Garcon, N.,Prieels, J. P., Slaoui, M., Thiriart, C. and Porter, D. D.(2001) Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19, 2048-2054. https://doi.org/10.1016/S0264-410X(00)00417-5
  42. Hancock, G. E., Heers, K. M., Pryharski, K. S., Smith, J. D.and Tiberio, L. (2003) Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21, 4348-4358. https://doi.org/10.1016/S0264-410X(03)00482-1
  43. Piedra, P. A., Cron, S. G., Jewell, A., Hamblett, N.,McBride, R., Palacio, M. A., Ginsberg, R., Oermann, C.M. and Hiatt, P. W. (2003) Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21, 2448-2460. https://doi.org/10.1016/S0264-410X(03)00098-7
  44. Tristram, D. A., Welliver, R. C., Mohar, C. K., Hogerman,D. A., Hildreth, S. W. and Paradiso, P. (1993) Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167, 191-195. https://doi.org/10.1093/infdis/167.1.191
  45. Groothuis, J. R., King, S. J., Hogerman, D. A., Paradiso, P.R. and Simoes, E. A. (1998) Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177, 467-469. https://doi.org/10.1086/517377
  46. de Waal, L., Power, U. F., Yuksel, S., van Amerongen, G.,Nguyen, T. N., Niesters, H. G., de Swart, R. L. andOsterhaus, A. D. (2004) Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22, 915-922. https://doi.org/10.1016/j.vaccine.2003.10.008
  47. Power, U. F., Nguyen, T. N., Rietveld, E., de Swart, R. L.,Groen, J., Osterhaus, A. D., de Groot, R., Corvaia, N.,Beck, A., Bouveret-Le-Cam, N. and Bonnefoy, J. Y. (2001)Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect Dis. 184, 1456-1460. https://doi.org/10.1086/324426
  48. Kohlmann, R., Schwannecke, S., Tippler, B., Ternette, N.,Temchura, V. V., Tenbusch, M., Uberla, K. and Grunwald,T. (2009) Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J. Virol. 83, 12601- 12610. https://doi.org/10.1128/JVI.01036-09
  49. Yu, J. R., Kim, S., Lee, J. B. and Chang, J. (2008) Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82, 2350-2357. https://doi.org/10.1128/JVI.02372-07
  50. Hsu, K. H., Lubeck, M. D., Davis, A. R., Bhat, R. A.,Selling, B. H., Bhat, B. M., Mizutani, S., Murphy, B. R.,Collins, P. L., Chanock, R. M. and Hung, P. P. (1992) Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J. Infect Dis. 166, 769-775. https://doi.org/10.1093/infdis/166.4.769
  51. Takimoto, T., Hurwitz, J. L., Zhan, X., Krishnamurthy, S.,Prouser, C., Brown, B., Coleclough, C., Boyd, K., Scroggs,R. A., Portner, A. and Slobod, K. S. (2005) Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral. Immunol. 18, 255-266. https://doi.org/10.1089/vim.2005.18.255
  52. Schmidt, A. C., McAuliffe, J. M., Murphy, B. R. and Collins,P. L. (2001) Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75, 4594-4603. https://doi.org/10.1128/JVI.75.10.4594-4603.2001
  53. Elliott, M. B., Chen, T., Terio, N. B., Chong, S. Y.,Abdullah, R., Luckay, A., Egan, M. A., Boutilier, L. A.,Melville, K., Lerch, R. A., Long, D., Eldridge, J. H., Parks,C. L., Udem, S. A. and Hancock, G. E. (2007) Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25, 7132-7144. https://doi.org/10.1016/j.vaccine.2007.07.065
  54. Mok, H., Lee, S., Utley, T. J., Shepherd, B. E., Polosukhin,V. V., Collier, M. L., Davis, N. L., Johnston, R. E. andCrowe, J. E. Jr. (2007) Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J. Virol. 81, 13710-13722. https://doi.org/10.1128/JVI.01351-07
  55. Cano, F., Plotnicky-Gilquin, H., Nguyen, T. N., Liljeqvist,S., Samuelson, P., Bonnefoy, J., Stahl, S. and Robert, A.(2000) Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18, 2743-2752. https://doi.org/10.1016/S0264-410X(00)00063-3
  56. Martinez-Sobrido, L., Gitiban, N., Fernandez-Sesma, A.,Cros, J., Mertz, S. E., Jewell, N. A., Hammond, S., Flano,E., Durbin, R. K., Garcia-Sastre, A. and Durbin, J. E.(2006) Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 80, 1130-1139. https://doi.org/10.1128/JVI.80.3.1130-1139.2006
  57. Bembridge, G. P., Rodriguez, N., Garcia-Beato, R., Nicolson,C., Melero, J. A. and Taylor, G. (2000) Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19, 1038-1046. https://doi.org/10.1016/S0264-410X(00)00344-3
  58. Li, X., Sambhara, S., Li, C. X., Ewasyshyn, M., Parrington,M., Caterini, J., James, O., Cates, G., Du, R. P. and Klein,M. (1998) Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188, 681-688. https://doi.org/10.1084/jem.188.4.681

Cited by

  1. The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in Human Skin Cancer Cell Line, A431 vol.15, pp.1, 2013, https://doi.org/10.5812/ircmj.4722
  2. Evaluation of Protective Efficacy of Respiratory Syncytial Virus Vaccine against A and B Subgroup Human Isolates in Korea vol.6, pp.9, 2011, https://doi.org/10.1371/journal.pone.0023797
  3. Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease vol.12, pp.1, 2012, https://doi.org/10.4110/in.2012.12.1.8
  4. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease vol.476, 2015, https://doi.org/10.1016/j.virol.2014.12.004
  5. In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus vol.57, pp.4, 2016, https://doi.org/10.3349/ymj.2016.57.4.809
  6. Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection vol.31, pp.37, 2013, https://doi.org/10.1016/j.vaccine.2013.05.088
  7. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines vol.48, pp.10, 2015, https://doi.org/10.5483/BMBRep.2015.48.10.268
  8. The Respiratory Syncytial Virus G Protein Conserved Domain Induces a Persistent and Protective Antibody Response in Rodents vol.7, pp.3, 2012, https://doi.org/10.1371/journal.pone.0034331
  9. Rapid replacement of human respiratory syncytial virus A with the ON1 genotype having 72 nucleotide duplication in G gene vol.26, 2014, https://doi.org/10.1016/j.meegid.2014.05.007
  10. Impact of Respiratory Syncytial Virus vol.11, pp.3, 2011, https://doi.org/10.2165/11593140-000000000-00000
  11. Strategic priorities for respiratory syncytial virus (RSV) vaccine development vol.31, 2013, https://doi.org/10.1016/j.vaccine.2012.11.106
  12. Innate immune recognition of respiratory syncytial virus infection vol.47, pp.4, 2014, https://doi.org/10.5483/BMBRep.2014.47.4.050
  13. Differential Roles of Lung Dendritic Cell Subsets Against Respiratory Virus Infection vol.14, pp.3, 2014, https://doi.org/10.4110/in.2014.14.3.128
  14. Central nervous system alterations caused by infection with the human respiratory syncytial virus vol.24, pp.6, 2014, https://doi.org/10.1002/rmv.1813
  15. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus vol.10, pp.6, 2015, https://doi.org/10.1371/journal.pone.0128779
  16. A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus vol.159, pp.5, 2014, https://doi.org/10.1007/s00705-013-1932-z
  17. Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus vol.11, pp.1, 2014, https://doi.org/10.1186/1743-422X-11-142
  18. Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus vol.8, pp.1, 2019, https://doi.org/10.7774/cevr.2019.8.1.43